What is the recommended tenecteplase (TNK) dose for an adult patient with acute ischemic stroke?

Tenecteplase Dosing for Acute Ischemic Stroke

For acute ischemic stroke, administer tenecteplase as a single intravenous bolus at 0.25 mg/kg (maximum dose 25 mg) within 4.5 hours of symptom onset. 1, 2

Dosing Protocol

Weight-based calculation:

• Calculate 0.25 mg/kg of actual body weight 1, 2
• Maximum dose is 25 mg regardless of weight 1, 2
• Administer as single IV bolus over 5-10 seconds 3

Critical distinction from STEMI dosing:

• The stroke dose (0.25 mg/kg, max 25 mg) differs from the STEMI dose (weight-tiered 30-50 mg) 2, 4
• Never use the higher STEMI dose of 0.5 mg/kg for stroke patients 2

Evidence Base and Guideline Support

The 0.25 mg/kg dose is supported by the highest quality evidence:

• The American Heart Association/American Stroke Association gives tenecteplase a Class IIb, Level B-R recommendation as an alternative to alteplase for patients with minor neurological impairment and no major intracranial occlusion 1, 3
• Recent meta-analysis of 11 RCTs (7,545 patients) demonstrates tenecteplase 0.25 mg/kg is superior to alteplase for excellent functional outcome (mRS 0-1) with risk ratio 1.05 (95% CI 1.01-1.10, p=0.012) 5
• The 2024 ORIGINAL trial (1,465 patients) established non-inferiority of tenecteplase 0.25 mg/kg to alteplase with 72.7% vs 70.3% achieving mRS 0-1 at 90 days 6

Avoid higher doses:

• The 0.4 mg/kg dose is associated with increased bleeding risk and is not recommended 3, 7
• The European Stroke Organisation explicitly recommends against using tenecteplase 0.40 mg/kg (low evidence, strong recommendation) 7

Time Window and Eligibility

Standard time window (0-4.5 hours):

• Tenecteplase 0.25 mg/kg can be used as an alternative to alteplase within 4.5 hours of symptom onset 8, 1
• Treatment should be initiated as rapidly as possible; every minute of delay reduces likelihood of favorable recovery 2

Extended window (4.5-24 hours) - select patients only:

• For patients with non-large vessel occlusion and salvageable tissue on perfusion imaging, tenecteplase 0.25 mg/kg administered 4.5-24 hours after onset improves excellent functional outcome (43.6% vs 34.2%, risk ratio 1.28) 9
• This extended window application requires advanced imaging (CT perfusion or DW-MRI) to demonstrate salvageable tissue 9

Pre-Administration Requirements

Blood pressure control:

• Systolic BP must be <185 mmHg and diastolic BP <110 mmHg before administration 3
• Severe uncontrolled hypertension (SBP >180 mmHg or DBP >110 mmHg unresponsive to therapy) is an absolute contraindication 3

Imaging and laboratory:

• Non-contrast head CT must exclude intracranial hemorrhage 2
• Blood glucose must be >50 mg/dL 2
• CT must exclude extensive hypoattenuation indicating irreversible injury 2

Absolute Contraindications

Do not administer tenecteplase if:

• Any prior intracranial hemorrhage 3
• Ischemic stroke within previous 3 months 2
• Recent major trauma or surgery within 3 months 2
• Unknown or unwitnessed symptom onset with last-known-well time >4.5 hours 2
• Active internal bleeding 4
• Known bleeding diathesis 4

Administration Technique

Reconstitution and delivery:

• Reconstitute 50 mg vial with 10 mL Sterile Water for Injection to achieve 5 mg/mL concentration 4
• Draw calculated dose volume in mL (dose in mg ÷ 5 mg/mL) 4
• Flush dextrose-containing IV lines with 0.9% sodium chloride before and after administration 4
• Administer as single bolus over 5-10 seconds 3, 4

Post-Administration Management

Immediate monitoring (first 30 minutes):

• Observe closely for orolingual angioedema (facial, tongue, or lip swelling) 1
• If angioedema develops: discontinue ACE-inhibitor, give IV methylprednisolone, diphenhydramine, H₂-blocker; consider epinephrine if progressing 1

Neurological surveillance:

• Perform neurological assessments every 15 minutes during and immediately after bolus 3
• Continue assessments every 30 minutes for 6 hours post-administration 3
• Any clinical deterioration warrants immediate repeat neuroimaging 1

Blood pressure management:

• Maintain systolic BP ≤180 mmHg and diastolic BP ≤105 mmHg for at least 24 hours 3
• Frequent blood pressure monitoring required 3

Antiplatelet therapy timing:

• Aspirin must be delayed for at least 24 hours after tenecteplase 1
• Obtain repeat non-contrast CT or MRI at 24 hours to exclude hemorrhagic transformation 1
• Once imaging confirms no hemorrhage, administer aspirin 160-300 mg loading dose 1
• Aspirin must never postpone tenecteplase administration 1

Advantages Over Alteplase

Practical benefits of tenecteplase:

• Single-bolus administration eliminates need for 60-minute infusion 1, 2
• Reduces nursing time and potential medication errors 1
• Longer half-life (90-130 minutes) vs alteplase 4
• Superior fibrin specificity for more targeted clot dissolution 10
• Significant workflow advantages for centers performing endovascular therapy or patient transfers 1

Safety Profile

Hemorrhage risk:

• Symptomatic intracranial hemorrhage rate approximately 1.2% with tenecteplase 0.25 mg/kg, similar to alteplase 6
• In extended window (4.5-24 hours), symptomatic ICH rate 2.8% vs 0% with standard care 9
• Overall absolute increase in symptomatic ICH with thrombolysis is approximately 6% (number needed to harm = 17) 1

Mortality:

• 90-day mortality 4.6% with tenecteplase vs 5.8% with alteplase (not statistically different) 6
• No significant difference in mortality between tenecteplase and control in extended window trials 11

Special Populations

Large vessel occlusion:

• For patients with LVO within 4.5 hours who are IVT-eligible, tenecteplase 0.25 mg/kg is recommended over alteplase (moderate evidence, strong recommendation) 7
• Patients eligible for IV thrombolysis should receive it even if endovascular therapy is being considered 8
• Do not evaluate response to tenecteplase before proceeding with mechanical thrombectomy 8

Wake-up stroke:

• For patients who awoke with stroke symptoms or have unclear time of onset >4.5 hours from last known well, tenecteplase is not recommended with non-contrast CT alone 7
• Advanced imaging (MRI showing DWI-FLAIR mismatch) may identify candidates for treatment 8